A Harvard University researcher is urging Pfizer to split its cholesterol drugs to allow patients a better shot at improving their health. Pfizer has been under attack for considering a plan to market its new drug torcetrapib for lowering LDL, or bad cholesterol, in combination with Lipitor, which raises HDL, or good cholesterol. A number of researchers, though, say the drugs should be sold separately to provide patients with greater choices. Pfizer has been accused of proposing a combination because its patent for Lipitor will expire in 2010. Analysts say a combination pill could be worth up to $15 billion per year for Pfizer.
- read this story from the Los Angeles Times for more
ALSO: Pfizer is planning to outsource some of its IT work to India as part of a cost-saving plan. Story